Market Overview
Size, incidence, and mix shift
- Brevintel analysis values the U.S. prostate-specific antigen test market at USD 1.5 billion in 2025 ($1.5B), rising from USD 1.6 billion in 2026 to USD 2.7 billion by 2035 ($2.7B) at a 6.1% CAGR.
- Headline cards list $1.5B, $2.7B, and 5.7% CAGR, while the narrative outlook uses a 6.1% CAGR; both token sets are retained because 5.7% is also the preliminary-test forecast rate.
- Growth is a mix shift: recurring high-volume total PSA, free PSA, and related assays across screening and surveillance, plus rising revenue from risk-stratification tests after an elevated result.
- The American Cancer Society estimated 313,780 new U.S. prostate cancer cases in 2025, while NCI projected 333,830 new cases and 36,320 deaths for 2026.
- An estimated 3.7 million men were living with prostate cancer in the United States in 2023, creating a large base for serial PSA measurement after treatment and during active surveillance.
- Quest Diagnostics led with over 18% market share in 2025; F. Hoffmann-La Roche, LabCorp, Siemens Healthineers, MDxHealth, and Quest Diagnostics collectively held 46%.
- PSA testing among men aged 55-69 was 38.0% in 2023, including 33.5% among non-Hispanic Black men versus 41.8% among non-Hispanic White men, based on NCI testing-rate reporting for 2005-2023.
- Incidence rose 2.7% annually during 2014-2023 after an earlier decline, while localized disease has a 5-year relative survival rate of 98.2%, leaving a large follow-up cohort.
Market Dynamics
Clinical and technology drivers
- Survivorship amplifies testing demand because PSA trajectories are used to identify biochemical recurrence and to assess active surveillance long after diagnosis.
- Black men have markedly higher incidence and mortality but lower reported screening participation than White men, so risk-based outreach can lift first-line PSA volume and confirmatory follow-up.
- Siemens Healthineers received FDA premarket approval in December 2025 for Atellica IM Total PSA II, standardized against the WHO 17/100 reference material.
- Siemens offers PSA, free PSA, and complexed PSA across Atellica IM, ADVIA Centaur, Dimension Vista, and IMMULITE platforms, while Roche Elecsys total PSA runs on cobas e immunoassay systems.
- Beckman Coulter's Prostate Health Index combines total PSA, free PSA, and p2PSA to support risk assessment in the diagnostic gray zone.
- Cleveland Diagnostics' IsoPSA received FDA approval in December 2025 as an aid to biopsy decision-making for men aged 50 years and older with elevated PSA, using structural variants rather than concentration alone.
- The USPSTF recommends individualized decision-making for men aged 55-69 and recommends against routine screening in men aged 70 years and older, while Medicare covers annual PSA screening for eligible men aged 50 years and older under National Coverage Determination 210.1.
- FDA-approved 4Kscore testing incorporates four kallikrein biomarkers and clinical variables; a meta-analysis reported pooled discrimination for high-grade disease with an area under the curve exceeding 0.80.
Cost, coverage, and guideline constraints
- Routine PSA testing benefits from established laboratory workflows and a defined Medicare screening benefit, whereas advanced protein, RNA, and tissue-based assays face fragmented reimbursement.
- Coverage policies identify eligible uses for tests such as 4Kscore, ExoDx, SelectMDx, and ConfirmMDx, but requirements vary by payer and test category.
- Laboratories and urology practices can justify routine PSA at scale yet still route specialized biomarkers to national reference laboratories, adding authorization and specimen-routing friction.
- PSA screening remains contested because benefits depend on patient selection, follow-up quality, and avoidance of unnecessary biopsy or treatment.
- The USPSTF Grade C recommendation for ages 55-69 formalizes shared decision-making rather than population-wide routine screening, while the Grade D recommendation for men aged 70 years and older limits primary-care standardization.
- Brevintel analysis finds the cost restraint more manageable where advanced tests demonstrate a role in avoiding low-yield biopsy; IsoPSA and 4Kscore are positioned around a specific clinical decision rather than as replacements for routine PSA.
- Guideline fragmentation is likely to persist because it reflects trade-offs around overdiagnosis, life expectancy, and preference, but shared decision-making still makes PSA an entry point into risk-stratified care.
Segmentation Analysis
Product
- Preliminary tests accounted for 73.4% of market revenue in 2025, or approximately USD 1,101 million, and are projected to reach USD 2.0 billion by 2035 at a CAGR of 5.7%.
- Source FAQs also state that preliminary tests are expected to reach USD 2 billion by 2035, matching the USD 2.0 billion forecast for total PSA, free PSA, and related first-line assays.
- Total PSA is the highest-volume preliminary component because it is used across screening, post-treatment monitoring, and active surveillance, with economics shaped by automation and WHO 17/100 comparability.
- Free PSA is most relevant after an elevated total PSA result, particularly where benign disease and malignancy are difficult to distinguish, and Roche and Siemens offer free PSA on established platforms.
- Other preliminary tests include algorithmic assays such as PHI, 4Kscore, and IsoPSA, which address the same biopsy-decision bottleneck through multi-marker or structural-variant methods.
- Confirmatory tests generated USD 408.4 million in 2025, capturing higher-value decisions after an abnormal PSA result, including lesion localization, biopsy guidance, tissue characterization, and genomic risk assessment.
- Multiparametric MRI and MRI/ultrasound fusion systems are increasingly embedded in workup; GE HealthCare tools support automated prostate segmentation, PSA density calculation, and lesion localization, while Philips DynaCAD Prostate and UroNav connect MRI analysis with fusion-biopsy workflows.
- Veracyte's Decipher Prostate was identified as the only gene-expression test in the NCCN Prostate Cancer Guidelines' 2025 Advanced Tools table with Level 1B evidence, and Myriad's Prolaris supports surveillance versus treatment decisions.
- MDxHealth's September 2025 acquisition of Exosome Diagnostics added ExoDx Prostate and a CLIA-certified laboratory alongside SelectMDx, ConfirmMDx, and Genomic Prostate Score services.
Application
- Prostate cancer screening generated USD 908.7 million in 2025, supported by Medicare coverage for annual PSA screening among eligible men aged 50 years and older.
- Screening growth is moderated by guideline-directed shared decision-making and uneven uptake among risk groups, including the 38.0% testing rate among men aged 55-69 in 2023.
- Prostate cancer monitoring represented 40.8% of 2025 revenue, or approximately USD 612 million, with repeated measurements after treatment, during active surveillance, or while evaluating biochemical recurrence.
- Monitoring has a structurally different utilization pattern from screening and is less sensitive to first-time screening participation because of the expanding prevalent population and high survival rate.
- Brevintel analysis treats screening as the diagnostic funnel and monitoring as the durable, serial-testing pool that keeps total PSA indispensable even when confirmatory assays capture more value per decision.
End use
- Independent commercial reference laboratories held 35.9% of market revenue in 2025, or approximately USD 538.5 million, processing high-volume routine PSA and distributing specialty assays that smaller sites may not perform internally.
- Quest Diagnostics and LabCorp operate the largest independent networks, offering high-volume processing, rapid turnaround, and nationwide access for both commodity immunoassays and selected specialty diagnostics.
- Hospital-based laboratories accounted for 30.7% of revenue in 2025, or approximately USD 460.5 million, retaining testing when rapid results, pathology integration, MRI access, or multidisciplinary case management matter more than unit cost.
- Physician practice-owned central laboratories generated USD 427.1 million in 2025, competing on a shorter interval between testing and a urology consultation or biopsy decision.
- Compact immunoassay systems, reflex testing, and point-of-care formats can be attractive in physician-owned settings, but adoption is constrained by capital requirements, quality oversight, and reimbursement.
- Other end users include public health, Veterans Affairs, and community-based care settings, which matter for access expansion where centralized reference testing serves rural or resource-constrained practices.
- Brevintel estimates show a clear revenue bifurcation: preliminary tests at 73.4% of 2025 revenue versus confirmatory tests at USD 408.4 million with greater value per clinical decision.
Regional Outlook
South and Northeast
- The South provides a substantial volume base for PSA testing because of its large older male population, including major Medicare markets in Florida and Texas.
- Elevated disease burden among Black men makes targeted screening access particularly important across parts of the South, where scalable routine testing and follow-up after an elevated result determine utilization.
- The Northeast has dense academic medical center, cancer-center, and specialist-laboratory infrastructure capable of integrating prostate MRI, biopsy navigation, tissue genomics, and multidisciplinary treatment planning.
- Northeast settings support earlier uptake of premium confirmatory assays where private insurance coverage and specialist referral networks facilitate adoption.
- Brevintel analysis frames the South as the largest base for standardized screening and monitoring volume, with laboratory access, Medicare participation, and primary-care outreach as the conversion levers.
- Across regions, rural access remains a limiting factor because lower specialist density, transportation barriers, and reduced local laboratory capacity can delay confirmatory workup after a PSA result.
Midwest and West
- The Midwest combines large integrated health systems with diagnostics operations and academic referral centers, supporting high-throughput routine PSA alongside advanced biomarkers, imaging, and genomic classifiers.
- The West is an important innovation market for advanced prostate cancer management, supported by specialist urology practices, academic medical centers, and imaging infrastructure.
- Philips reports that its prostate cancer imaging solution is deployed at 22 of the 25 top U.S. cancer hospitals, illustrating how high-end imaging systems concentrate in leading specialist settings.
- Western commercial opportunity is therefore weighted toward MRI-enabled diagnostic pathways and testing that supports active-surveillance and treatment-selection decisions.
- Centralized reference testing and digitally enabled referral pathways can mitigate some rural friction, but they do not fully replace local access to urology, MRI, and biopsy services.
- Immunoassay manufacturers and reference laboratories benefit from broad contracts and specimen logistics, whereas advanced-test developers need focused coverage across urology groups, cancer centers, pathology departments, and MRI-enabled sites.
- Geographic strategy should follow the site of clinical decision-making rather than population size alone, pairing Sun Belt volume with Northeast and West premium-test concentration.
Competitive Landscape
Structure and recent developments
- Competition is organized around diagnostic roles: immunoassay suppliers compete on installed base, throughput, WHO 17/100 standardization, and connectivity, while specialist biomarker and genomic companies compete on evidence, coverage, and biopsy or treatment influence.
- Quest Diagnostics led with over 18% share in 2025, and the top five held 46%, spanning laboratory networks and platform vendors rather than a single product category.
- Abbott participates through its immunoassay footprint and, following its March 2026 acquisition of Exact Sciences, through broader oncology diagnostics capabilities.
- Danaher, primarily through Beckman Coulter Diagnostics, competes with Access immunoassay platforms and the PHI multi-marker test that helps laboratories retain PSA reflex work.
- Cleveland Diagnostics is differentiated by IsoPSA, which received FDA approval in December 2025 as a biopsy decision-support test for eligible patients with elevated PSA.
- Siemens Healthineers maintains PSA assays across Atellica IM, ADVIA Centaur, Dimension Vista, and IMMULITE systems, with December 2025 tPSAII approval supporting migration toward newer automated architecture.
- GE HealthCare, Koelis, and Philips participate in confirmatory imaging and biopsy guidance, while Glycanostics represents an emerging PSA glycoform approach that still needs broader clinical validation.
- Advacare Pharma and CTK Biotech address rapid-test and decentralized formats where an office or community setting values simple PSA assessment without a large automated analyzer.
Integrated producers
- Quest Diagnostics
- LabCorp
- F. Hoffmann-La Roche
- Siemens Healthineers
- Abbott
- Danaher
Specialty suppliers
- MDxHealth
- Cleveland Diagnostics
- Myriad Genetics
- OPKO Health
- Veracyte